{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:45:09Z","timestamp":1778568309216,"version":"3.51.4"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In phase 3 trials, inactivated varicella zoster virus (VZV) vaccine (ZVIN) was well tolerated and efficacious against herpes zoster (HZ) in autologous hematopoietic stem cell transplant (auto-HSCT) recipients and patients with solid tumor malignancies receiving chemotherapy (STMc) but did not reduce HZ incidence in patients with hematologic malignancies (HMs). Here, we describe ZVIN immunogenicity from these studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients were randomized to ZVIN or placebo (4 doses). Immunogenicity was assessed by glycoprotein enzyme-linked immunosorbent assay (gpELISA) and VZV interferon (IFN)-\u03b3 enzyme-linked immunospot (ELISPOT) assay in patients receiving all 4 doses without developing HZ at the time of blood sampling.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Estimated geometric mean fold rise ratios (ZVIN\/placebo) by gpELISA and IFN-y ELISPOT ~28 days post\u2013dose 4 were 2.02 (95% confidence interval [CI], 1.53\u20132.67) and 5.41 (95% CI, 3.60\u20138.12) in auto-HSCT recipients; 1.88 (95% CI, 1.79\u20131.98) and 2.10 (95% CI, 1.69\u20132.62) in patients with STMc; and not assessed and 2.35 (95% CI, 1.81\u20133.05) in patients with HM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>ZVIN immunogenicity was directionally consistent with clinical efficacy in auto-HSCT recipients and patients with STMc even though HZ protection and VZV immunity were not statistically correlated. Despite a lack of clinical efficacy in patients with HM, ZVIN immunogenicity was observed in this population. Immunological results did not predict vaccine efficacy in these 3 populations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical trial registration<\/jats:title>\n                  <jats:p>NCT01229267, NCT01254630.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaa172","type":"journal-article","created":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T22:40:01Z","timestamp":1591051201000},"source":"Crossref","is-referenced-by-count":10,"title":["Immunogenicity of Inactivated Varicella Zoster Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients and Patients With Solid or Hematologic Cancer"],"prefix":"10.1093","volume":"7","author":[{"given":"Michael J","family":"Boeckh","sequence":"first","affiliation":[{"name":"Vaccine and Infectious Disease & Clinical Research Divisions, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann M","family":"Arvin","sequence":"first","affiliation":[{"name":"Microbiology & Immunology Departments, Stanford University School of Medicine, Stanford, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen M","family":"Mullane","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Chicago, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis H","family":"Camacho","sequence":"first","affiliation":[{"name":"Medical Oncology, Oncology Consultants, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drew J","family":"Winston","sequence":"first","affiliation":[{"name":"Department of Medicine, University of California Los Angeles Medical Center, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicki A","family":"Morrison","sequence":"first","affiliation":[{"name":"Hematology Oncology Division, Hennepin County Medical Center, University of Minnesota, Minneapolis, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Hurtado","sequence":"first","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessie","family":"Durrand Hall","sequence":"first","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Pang","sequence":"first","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Chih","family":"Su","sequence":"first","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan S","family":"Kaplan","sequence":"first","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula W","family":"Annunziato","sequence":"first","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoran","family":"Popmihajlov","sequence":"first","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"V212 Protocol 001 Trial Group and V212 Protocol 011 Trial Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"key":"2020070607541498400_CIT0001","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s15010-013-0550-8","article-title":"Incidence of herpes zoster in patients with altered immune function","volume":"42","author":"Chen","year":"2014","journal-title":"Infection"},{"key":"2020070607541498400_CIT0002","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1158\/1055-9965.EPI-12-0815","article-title":"The epidemiology of herpes zoster in patients with newly diagnosed cancer","volume":"22","author":"Habel","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2020070607541498400_CIT0003","doi-asserted-by":"crossref","first-page":"e8746","DOI":"10.1097\/MD.0000000000008746","article-title":"Healthcare utilization and costs among patients with herpes zoster and solid tumor malignancy on chemotherapy: a retrospective cohort study","volume":"96","author":"Mao","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"2020070607541498400_CIT0004","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/03007995.2017.1384374","article-title":"Herpes zoster incidence and cost in patients receiving autologous hematopoietic stem-cell transplant","volume":"34","author":"Mao","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"2020070607541498400_CIT0005","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.cger.2007.03.003","article-title":"Herpes zoster and postherpetic neuralgia in older adults","volume":"23","author":"Schmader","year":"2007","journal-title":"Clin Geriatr Med"},{"key":"2020070607541498400_CIT0006","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12879-015-0810-6","article-title":"The epidemiology of herpes zoster and its complications in Medicare cancer patients","volume":"15","author":"Yenikomshian","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2020070607541498400_CIT0007","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/S0140-6736(18)30631-7","article-title":"Inactivated varicella zoster vaccine in autologous hematopoietic stem cell transplantation: an international, multicentre, randomized, double-blind, placebo-controlled trial","volume":"391","author":"Winston","year":"2018","journal-title":"Lancet"},{"key":"2020070607541498400_CIT0008","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S1473-3099(19)30310-X","article-title":"Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial","volume":"19","author":"Mullane","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2020070607541498400_CIT0009","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/s12879-015-1262-8","article-title":"Annual incidence rates of herpes zoster among an immunocompetent population in the United States","volume":"15","author":"Johnson","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2020070607541498400_CIT0010","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1007\/s12325-016-0355-0","article-title":"Real-world effectiveness and safety of a live-attenuated herpes zoster vaccine: a comprehensive review","volume":"33","author":"Ansaldi","year":"2016","journal-title":"Adv Ther"},{"key":"2020070607541498400_CIT0011","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020070607541498400_CIT0012","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/510206","article-title":"Recommendations for the management of herpes zoster","volume":"44(","author":"Dworkin","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020070607541498400_CIT0013","first-page":"1","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"2020070607541498400_CIT0014","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMcp013211","article-title":"Clinical practice. Herpes zoster","volume":"347","author":"Gnann","year":"2002","journal-title":"N Engl J Med"},{"key":"2020070607541498400_CIT0015","volume-title":"ZOSTAVAX\u00ae (Zoster Vaccine Live) [prescribing information]","year":"2018"},{"key":"2020070607541498400_CIT0016","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa013441","article-title":"Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants","volume":"347","author":"Hata","year":"2002","journal-title":"N Engl J Med"},{"key":"2020070607541498400_CIT0017","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/infdis\/jit344","article-title":"Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults","volume":"208","author":"Mullane","year":"2013","journal-title":"J Infect Dis"},{"key":"2020070607541498400_CIT0018","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1086\/514077","article-title":"Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine","volume":"176","author":"Redman","year":"1997","journal-title":"J Infect Dis"},{"key":"2020070607541498400_CIT0019","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/cid\/cix484","article-title":"Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with autoimmune disease: a phase 2, randomized, double-blind, placebo-controlled clinical trial","volume":"65","author":"Eberhardson","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020070607541498400_CIT0020","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.vaccine.2016.10.055","article-title":"Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies","volume":"35","author":"Parrino","year":"2017","journal-title":"Vaccine"},{"key":"2020070607541498400_CIT0021","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0166-0934(86)90048-0","article-title":"Purification of individual varicella-zoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies","volume":"14","author":"Keller","year":"1986","journal-title":"J Virol Methods"},{"key":"2020070607541498400_CIT0022","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1128\/CDLI.8.5.871-879.2001","article-title":"Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus","volume":"8","author":"Smith","year":"2001","journal-title":"Clin Diagn Lab Immunol"},{"key":"2020070607541498400_CIT0023","first-page":"134","article-title":"Longitudinal data analysis of continuous and discrete responses for pre-post designs","volume":"62","author":"Liang","year":"2000","journal-title":"Sankhya\u0304: Indian J Stat (Ser B)"},{"key":"2020070607541498400_CIT0024","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"2020070607541498400_CIT0025","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020070607541498400_CIT0026","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"J Infect Dis"},{"key":"2020070607541498400_CIT0027","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/infdis\/jit342","article-title":"Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine","volume":"208","author":"Levin","year":"2013","journal-title":"J Infect Dis"},{"key":"2020070607541498400_CIT0028","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1083-8791(00)70004-8","article-title":"Varicella-zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients","volume":"6","author":"Arvin","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020070607541498400_CIT0029","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bbmt.2012.08.015","article-title":"A randomized trial of one versus two doses of influenza vaccine after allogeneic transplantation","volume":"19","author":"Karras","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020070607541498400_CIT0030","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/bmt.2008.264","article-title":"Influenza vaccination in hematopoietic SCT recipients","volume":"42","author":"Ljungman","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"2020070607541498400_CIT0031","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/TP.0b013e3181772a75","article-title":"Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation","volume":"86","author":"Avetisyan","year":"2008","journal-title":"Transplantation"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaa172\/33334729\/ofaa172.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/7\/ofaa172\/33466756\/ofaa172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/7\/ofaa172\/33466756\/ofaa172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T11:54:32Z","timestamp":1594036472000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa172\/5850043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,2]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaa172","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2020,6,2]]},"article-number":"ofaa172"}}